Trial Profile
A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Gilteritinib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 01 Oct 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia
- 07 Jul 2021 Planned End Date changed from 30 Jun 2021 to 31 Jul 2021.
- 07 Jul 2021 Planned primary completion date changed from 30 Jun 2021 to 31 Jul 2021.